AGOURA HILLS, Calif., Aug. 17, 2022 Oncotelic Therapeutics, Inc. , developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that. | August 17, 2022
Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Rating) was the recipient of a significant growth in short interest in May. As of May 31st, there was short interest totalling 5,700 shares, a growth of 119.2% from the May 15th total of 2,600 shares. Based on an average daily trading volume, of 299,300 shares, the short-interest ratio […]
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ImmunoGen (NASDAQ:IMGN – Get Rating) and Oncotelic Therapeutics (OTCMKTS:OTLC – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations. Valuation and Earnings This table compares ImmunoGen and Oncotelic Therapeutics’ […]